Cardiff Oncology, Inc.
CRDF
$2.41
-$0.03-1.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -24.87% | -21.44% | -9.63% | -5.34% | -3.07% |
| Total Depreciation and Amortization | -4.66% | 22.24% | 69.10% | 78.48% | 93.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 41.09% | 20.98% | 16.00% | -0.96% | -22.84% |
| Change in Net Operating Assets | -20.46% | -83.17% | -55.80% | 14.34% | 110.16% |
| Cash from Operations | -30.50% | -42.64% | -22.04% | -4.31% | 1.84% |
| Capital Expenditure | 93.55% | 100.00% | 86.25% | 86.44% | 48.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -167.14% | -116.08% | -62.45% | -24.54% | 14.66% |
| Cash from Investing | -167.97% | -116.39% | -62.07% | -23.19% | 16.25% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,284.20% | 50,064.49% | -- | -- | 2,786.67% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,284.20% | 50,064.49% | -- | -- | 2,786.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -340.00% | 49.33% | 461.70% | 37.00% | 484.21% |